SUTRO BIOPHARMA, INC.: Coastlands Capital LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Coastlands Capital LP disclosed a stake of more than 5% in Sutro Biopharma Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-124373). The passive-investor disclosure signals a new large holder in the clinical-stage biotech, though the filing did not specify the exact share count or percentage above the 5% threshold. The move matters because 13G stakes can presage engagement or simply reflect index and fund positioning in a thinly traded name. Investors will watch for an amended 13G or 13D that clarifies intent, along with any subsequent changes in Coastlands' position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Coastlands Capital LP, Sutro Biopharma, Inc.